8-K: Neuraxis Amends Financing Agreement, Secures Additional Investment

Neuraxis, Inc. has amended its securities purchase agreement with Flagstaff International, reducing the total investment amount while also entering into new agreements with other investors for additional capital.

Summary

• Neuraxis, Inc. has modified its existing securities purchase agreement with Flagstaff International, LLC, reducing the total investment from $5 million to $1.8 million.
• Flagstaff International has already paid $800,000, and will pay an additional $500,000 by November 27, 2024, and another $500,000 by December 31, 2024.
• The company will issue up to 756,303 shares of Series B Preferred Stock to Flagstaff International.
• The agreement with Flagstaff International will terminate upon full payment and share issuance, mutual consent, or uncured breaches by either party by January 9, 2025.
• Neuraxis also entered into new securities purchase agreements with several investors to sell 60,924 shares of Series B Preferred Stock for approximately $145,000.
• The Series B Preferred Stock is convertible into common stock and ranks senior to common stock in liquidation.
• The stated value of the Series B Preferred Stock is $2.38 per share, with dividend and liquidation rights expiring on June 30, 2025.
• The company has agreed to file a resale registration statement with the SEC within 30 days and use its best efforts to have it declared effective.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has secured additional funding, the reduction in the Flagstaff investment is a concern. The new investment is relatively small and the company is dependent on future payments from Flagstaff.

Positives

• The company has secured additional funding through new investors.
• The company has clarified the terms of the Flagstaff International agreement.
• The company has a clear path to register the shares for resale.

Negatives

• The total investment from Flagstaff International was reduced from the previously agreed $5 million to $1.8 million.
• The company is relying on additional payments from Flagstaff International to be received by November 27, 2024 and December 31, 2024.
• The dividend and liquidation rights of the Series B Preferred Stock expire on June 30, 2025.

Risks

• There is a risk that Flagstaff International may not make the remaining payments by the agreed dates.
• The company's ability to raise additional capital may be impacted by the reduced investment from Flagstaff International.
• The company is dependent on the SEC declaring the resale registration statement effective.

Future Outlook

The company intends to use the proceeds from the sale of Series B Preferred Stock for working capital and general corporate purposes. They will also file a resale registration statement with the SEC within 30 days.

Industry Context

This announcement reflects a common practice of biotech companies to secure funding through private placements of preferred stock. The amendment to the Flagstaff agreement suggests a potential shift in the company's financing strategy or a change in Flagstaff's investment appetite.

Comparison to Industry Standards

• The use of convertible preferred stock is a common financing method for early-stage biotech companies, similar to companies like XOMA Corporation and Agenus Inc.
• The valuation of $2.38 per share for the Series B Preferred Stock is within the range of similar private placements in the biotech sector, but specific comparisons would require more detailed financial information.
• The requirement to file a resale registration statement is standard practice to provide liquidity to investors in private placements, similar to the agreements made by companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated.

Stakeholder Impact

• Shareholders may be concerned about the reduced investment from Flagstaff International.
• New investors will gain a stake in the company through the purchase of Series B Preferred Stock.
• The company's employees may be impacted by the company's financial situation.

Next Steps

• Flagstaff International is expected to make additional payments of $500,000 by November 27, 2024, and $500,000 by December 31, 2024.
• Neuraxis will file a resale registration statement with the SEC within 30 days.
• The company will work to have the registration statement declared effective by the SEC.

Key Dates

Keywords

securities purchase agreement, Series B Preferred Stock, investment, capital raise, registration rights, convertible stock, Flagstaff International, Neuraxis